['crohn disease']
['ged-0301', 'placebo']

        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          -  Male or female ≥ 18 years

          -  Active Crohn's disease (CD) disease as determined by the Crohn's Disease Activity
             Index (CDAI) score and the Simple Endoscopic Score for Crohn's Disease (SES-CD)

          -  Must meet a determined average minimum number of daily stools or rating of abdominal
             pain over a 7 day period

          -  Subject must have failed or experienced intolerance to at least one of the following:
             budesonide; systemic corticosteroids; immunosuppressants (eg, azathiopurine,
             6-mercaptopurine, or methotrexate); or biologics for the treatment of CD.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

          -  Diagnosis of ulcerative colitis (UC), indeterminate colitis, ischemic colitis,
             microscopic colitis, radiation colitis or diverticular disease-associated colitis

          -  Local manifestations of Crohn's Disease (CD) such as symptomatic/severe strictures,
             abscesses, short bowel syndrome; or other disease complications for which surgery
             might be indicated or could confound the evaluation of efficacy

          -  Intestinal resection within 6 months or any intra-abdominal surgery within 3 months
             prior to the Screening Visit

          -  Ileostomy or a colostomy

          -  Subject has a history of any clinically significant medical condition that, in the
             investigator's opinion, would prevent the subject from participating in the study.
      